AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16225652 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous prednisolone treatment during the entire induction phase
Number of subjects: 299
Study 16225652 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone given for 2 weeks of each cycle in combination with VMCP-IFN-alpha 2b
Number of subjects: 299
Study 11872200 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/d 17beta‐estradiol orally for 90 days
Number of subjects: 24
Study 11872200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10211871 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous (i.v.) infusion of zaleplon
Number of subjects: 23
Study 10211871 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg intravenous (i.v.) infusion of zaleplon
Number of subjects: 23
Study 10211871 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral dose of zaleplon
Number of subjects: 23
Study 10211871 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous (i.v.) infusion of zaleplon
Number of subjects: 23
Study 7796762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy, community mobilization to effect change in water contact habits and faecal disposal
Number of subjects: 0
Study 2258876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice for three months
Number of subjects: 35
Study 2258876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary advice)
Number of subjects: 35
Study 7192119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 60 mg LCB-29
Number of subjects: 3
Study 7192119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 400 mg LCB-29
Number of subjects: 3
Study 7192119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment application of 400 mg or 7 X 200 mg LCB-29
Number of subjects: 3
Study 29402402 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gum (200 mg) administered at 01:00 h, 03:00 h, 05:00 h, and 07:00 h during sleep deprivation
Number of subjects: 23
Study 29402402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 23
Study 29402402 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gum (200 mg)
Number of subjects: 23
Study 28095883 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitudes plus Specialist Treatment as Usual (STAU)
Number of subjects: 160
Study 28095883 — intervention group
Group type: COMPARATOR
Intervention: Specialist Treatment as Usual (STAU) alone
Number of subjects: 160
Study 28095883 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitudes plus STAU
Number of subjects: 160
Study 28095883 — intervention group
Group type: COMPARATOR
Intervention: STAU alone
Number of subjects: 160
Study 25965709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral losmapimod (7.5 mg twice daily)
Number of subjects: 25500
Study 25965709 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25500
Study 23993142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast enhanced MR-mammography (MRM)
Number of subjects: 25
Study 23993142 — intervention group
Group type: COMPARATOR
Intervention: FDG positron emission computed tomography (PET-CT)
Number of subjects: 25
Study 23472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritic patients
Number of subjects: 100
Study 23472419 — intervention group
Group type: COMPARATOR
Intervention: Non-arthritic patients
Number of subjects: 100
Study 19689569 — intervention group
Group type: EXPERIMENTAL
Intervention: Born to Learn (BTL) curriculum conducted in monthly home visits
Number of subjects: 464
Study 19689569 — intervention group
Group type: COMPARATOR
Intervention: General child development education only
Number of subjects: 464
Study 17410888 — intervention group
Group type: EXPERIMENTAL
Intervention: Five single-step self-etch adhesive systems
Number of subjects: 98
Study 15319622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic oral rehydration solution (ORS) with non-digestible carbohydrates (NDC)
Number of subjects: 144
Study 15319622 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic oral rehydration solution (ORS) without non-digestible carbohydrates (NDC)
Number of subjects: 144
Study 11328413 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction retroperitoneal pelvic drainage (Group A)
Number of subjects: 143
Study 11328413 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage and no pelvic reperitonealization (Group B)
Number of subjects: 143
Study 11328413 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial closure of pelvic peritoneum with no drainage
Number of subjects: 143
Study 9590463 — intervention group
Group type: EXPERIMENTAL
Intervention: L-2-oxothiazolidine-4-carboxylic acid (OTC) 1,500 mg
Number of subjects: 37
Study 9590463 — intervention group
Group type: EXPERIMENTAL
Intervention: L-2-oxothiazolidine-4-carboxylic acid (OTC) 3,000 mg
Number of subjects: 37
Study 9590463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7929870 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral valproate after a 750 mg intravenous loading dose
Number of subjects: 0
Study 7929870 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of valproate after a 750 mg loading dose
Number of subjects: 0
Study 7929870 — intervention group
Group type: COMPARATOR
Intervention: Both oral and intravenous regimens
Number of subjects: 0
Study 7929870 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 0
Study 3300408 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 20 mg
Number of subjects: 300
Study 3300408 — intervention group
Group type: COMPARATOR
Intervention: nalbuphine 10 mg
Number of subjects: 300
Study 3300408 — intervention group
Group type: COMPARATOR
Intervention: naloxone 0.05 mg
Number of subjects: 300
Study 29263150 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ezetimibe/simvastatin (E/S)
Number of subjects: 18144
Study 29263150 — intervention group
Group type: COMPARATOR
Intervention: 40 mg placebo/simvastatin
Number of subjects: 18144
Study 28841852 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7 vaccination in wholly-vaccinated villages
Number of subjects: 232
Study 28841852 — intervention group
Group type: COMPARATOR
Intervention: Control group (children in villages not wholly vaccinated)
Number of subjects: 232
Study 28841852 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (at least 1 year of education)
Number of subjects: 232
Study 28841852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 232
Study 26654525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball games
Number of subjects: 46
Study 26654525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Number of subjects: 46
Study 26654525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball games and nutrition counseling
Number of subjects: 46
Study 26654525 — intervention group
Group type: COMPARATOR
Intervention: Control group without intervention
Number of subjects: 46
Study 24037890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of recombinant FSH (rFSH) pretreatment followed by 24 months of pulsatile GnRH therapy
Number of subjects: 13
Study 24037890 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile GnRH therapy alone for 24 months
Number of subjects: 13
Study 20382982 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 404
Study 20382982 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 404
Study 18798327 — intervention group
Group type: EXPERIMENTAL
Intervention: Late recanalization of occluded infarct-related arteries (IRA)
Number of subjects: 261
Study 16176058 — intervention group
Group type: COMPARATOR
Intervention: HP*1S allele frequency in blood group 0
Number of subjects: 621
Study 16176058 — intervention group
Group type: EXPERIMENTAL
Intervention: HP*1S allele frequency in the population sample
Number of subjects: 621
Study 16176058 — intervention group
Group type: EXPERIMENTAL
Intervention: HP*1S and HP*2 relationship
Number of subjects: 621
Study 16176058 — intervention group
Group type: EXPERIMENTAL
Intervention: HP*1 alleles in blood groups A, B, AB
Number of subjects: 621
Study 12668982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 13-15 mg/kg/d for 6 months
Number of subjects: 226
Study 12668982 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 226
Study 12668982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 226
Study 12668982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 10370357 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose ondansetron (0.6 mg/kg, maximum dose 32 mg)
Number of subjects: 31
Study 10370357 — intervention group
Group type: COMPARATOR
Intervention: Multiple standard-dose ondansetron (0.15 mg/kg, maximum dose 8 mg, every 4 hr for four doses)
Number of subjects: 31
Study 8911803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfate-free electrolyte lavage solution (SF-ELS)
Number of subjects: 74
Study 8911803 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene glycol (PEG) solution
Number of subjects: 74
Study 1867232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day
Number of subjects: 8245
Study 1867232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day
Number of subjects: 8245
Study 1867232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 or 40 mg once or twice a day)
Number of subjects: 8245
Study 1867232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study 6617905 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-hCG plus dehydrogesterone (group 1)
Number of subjects: 20
Study 6617905 — intervention group
Group type: COMPARATOR
Intervention: CC-hCG (group 2)
Number of subjects: 20
Study 31497876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 660
Study 31497876 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss
Number of subjects: 660
Study 31497876 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 660
Study 31497876 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 660
Study 31476896 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission plasma glucose group II (higher glucose level)
Number of subjects: 5309
Study 31476896 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission plasma glucose group III (higher glucose level)
Number of subjects: 5309
Study 31476896 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission plasma glucose group IV (highest glucose level)
Number of subjects: 5309
Study 31476896 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 5309
Study 31476896 — intervention group
Group type: COMPARATOR
Intervention: Admission plasma glucose group I (lowest glucose level)
Number of subjects: 5309
Study 31476896 — intervention group
Group type: COMPARATOR
Intervention: Admission plasma glucose group II
Number of subjects: 5309
Study 31476896 — intervention group
Group type: COMPARATOR
Intervention: Admission plasma glucose group III
Number of subjects: 5309
Study 31476896 — intervention group
Group type: COMPARATOR
Intervention: Admission plasma glucose group IV
Number of subjects: 5309
Study 31476896 — intervention group
Group type: EXPERIMENTAL
Intervention: All glucose groups
Number of subjects: 5309
Study 28474286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D printed bone models
Number of subjects: 128
Study 28474286 — intervention group
Group type: COMPARATOR
Intervention: Electronic tablet animations
Number of subjects: 128
Study 26531850 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based medical automatic speech recognition (ASR) system
Number of subjects: 28
Study 26531850 — intervention group
Group type: COMPARATOR
Intervention: Self-typing (no ASR)
Number of subjects: 28
Study 23865593 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (receiving accelerometer-based feedback of daily walking activity)
Number of subjects: 0
Study 23865593 — intervention group
Group type: COMPARATOR
Intervention: No feedback group (not receiving accelerometer-based feedback)
Number of subjects: 0
Study 21329631 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 1,000 IU/ml
Number of subjects: 28
Study 21329631 — intervention group
Group type: COMPARATOR
Intervention: heparin 5,000 IU/ml
Number of subjects: 28
Study 19682544 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cTBS stimulation
Number of subjects: 20
Study 19682544 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 20
Study 17498108 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 306
Study 17498108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 15363874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate, 50mg once daily
Number of subjects: 564
Study 15363874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 11182748 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) started immediately after surgery
Number of subjects: 14
Study 11182748 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion during surgery and for 24 hours postoperatively
Number of subjects: 14
Study 10195003 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 9 gI
Number of subjects: 392
Study 10195003 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 12 gI
Number of subjects: 392
Study 10195003 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 9 gI
Number of subjects: 392
Study 10195003 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 12 gI
Number of subjects: 392
Study 7997919 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration program (treatment group)
Number of subjects: 303
Study 7997919 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 303
Study 3196530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium 145 mEq/L
Number of subjects: 5
Study 3196530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium 150 mEq/L
Number of subjects: 5
Study 3196530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium 155 mEq/L
Number of subjects: 5
Study 3196530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium 145 mEq/L to 155 mEq/L
Number of subjects: 5
Study 3196530 — intervention group
Group type: COMPARATOR
Intervention: Dialysate sodium (all levels)
Number of subjects: 5
Study 31747355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitafusion® Power C gummy (1000 mg)
Number of subjects: 30
Study 31747355 — intervention group
Group type: COMPARATOR
Intervention: Comparator caplet (1000 mg)
Number of subjects: 30
Study 30640777 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 269
Study 30640777 — intervention group
Group type: COMPARATOR
Intervention: Vehicle photodynamic therapy (VEH-PDT)
Number of subjects: 269
Study 28381266 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 840
Study 28381266 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 840
Study 25862116 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐mg sustained release (SR) melatonin for four weeks
Number of subjects: 11
Study 25862116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23299008 — intervention group
Group type: EXPERIMENTAL
Intervention: Puff City (Web-based tailored asthma intervention)
Number of subjects: 422
Study 23299008 — intervention group
Group type: COMPARATOR
Intervention: Generic asthma education (control)
Number of subjects: 422
Study 21689548 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-dependent conduction blockade of the inferior alveolar nerve (IAN) with continuous electrical stimulation for 3 minutes.
Number of subjects: 80
Study 21689548 — intervention group
Group type: COMPARATOR
Intervention: Mock electrical stimulation following IAN block.
Number of subjects: 80
Study 18283176 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg once at week 0
Number of subjects: 180
Study 18283176 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 100 mg every other week for 12 weeks
Number of subjects: 180
Study 18283176 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg weekly for 4 weeks
Number of subjects: 180
Study 18283176 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg every other week for 12 weeks
Number of subjects: 180
Study 18283176 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg weekly for 12 weeks
Number of subjects: 180
Study 18283176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 16626574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of autologous mononuclear bone marrow cells (BMCs)
Number of subjects: 18
Study 16626574 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 12666468 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 126
Study 12666468 — intervention group
Group type: COMPARATOR
Intervention: Group Treatment Control (GC)
Number of subjects: 126
Study 10968599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal clindamycin cream
Number of subjects: 237
Study 10968599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 8940218 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of conjugate heptavalent pneumococcal vaccine
Number of subjects: 0
Study 8940218 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of conjugate heptavalent pneumococcal vaccine
Number of subjects: 0
Study 8940218 — intervention group
Group type: COMPARATOR
Intervention: One dose of 23‐valent native polysaccharide vaccine
Number of subjects: 0
Study 8940218 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate pneumococcal vaccine
Number of subjects: 0
Study 1347191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125%
Number of subjects: 50
Study 1347191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (50 micrograms in 60 ml normal saline)
Number of subjects: 50
Study 1347191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine 0.125% and sufentanil (50 micrograms in 60 ml bupivacaine 0.125%)
Number of subjects: 50
Study 3886154 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (825 mg initial dose followed by 550 mg if symptoms persisted)
Number of subjects: 70
Study 3886154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 3886154 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 70
Study 31336124 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGNIFI-CD index
Number of subjects: 160
Study 31336124 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Van Assche index
Number of subjects: 160
Study 31336124 — intervention group
Group type: EXPERIMENTAL
Intervention: Van Assche index
Number of subjects: 160
Study 28322760 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame-based training program (8 weeks, 120 minutes per week)
Number of subjects: 83
Study 25550444 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-MOT training (10 sessions)
Number of subjects: 20
Study 25550444 — intervention group
Group type: COMPARATOR
Intervention: Nonactive control (CON)
Number of subjects: 20
Study 25092702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (180 mg dihydroartemisinin and 1,440 mg piperaquine administered as two consecutive daily doses once per month for a planned 4-month period)
Number of subjects: 69
Study 25092702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 22538450 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF-withdrawal (target area under the time-concentration curve-cyclosporine: 3250 ng·hr/mL)
Number of subjects: 177
Study 22538450 — intervention group
Group type: COMPARATOR
Intervention: CNI-withdrawal (target area under the time-concentration curve-mycophenolic acid: 75 μg·hr/mL)
Number of subjects: 177
Study 22538450 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF-withdrawal
Number of subjects: 177
Study 22538450 — intervention group
Group type: COMPARATOR
Intervention: CNI-withdrawal
Number of subjects: 177
Study 19576927 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments + intervention (worksite A)
Number of subjects: 151
Study 19576927 — intervention group
Group type: COMPARATOR
Intervention: Assessments only (worksite B)
Number of subjects: 151
Study 17514671 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antimicrobial prophylaxis
Number of subjects: 501
Study 17514671 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose antimicrobial prophylaxis
Number of subjects: 501
Study 14715853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 363
Study 12032113 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (10 units)
Number of subjects: 14
Study 12032113 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (10 units)
Number of subjects: 14
Study 12032113 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-acting human insulin (bedtime injection)
Number of subjects: 14
Study 9835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine pericardium buttressing on stapler
Number of subjects: 0
Study 9835005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no buttressing)
Number of subjects: 0
Study 8016794 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP treatment
Number of subjects: 18
Study 8016794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 2739867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral VUEFFE (VF)
Number of subjects: 42
Study 2739867 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 42
Study 4596491 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent classical Ogawa vaccine
Number of subjects: 0
Study 4596491 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent Inaba vaccine
Number of subjects: 0